An Interleukin-1 beta (IL1B) haplotype linked with psychosis transition is associated with IL1B gene expression and brain structure.

Adult Female Gene Expression / genetics Gray Matter / pathology Haplotypes Humans Interleukin-1beta / genetics Lateral Ventricles / pathology Male Middle Aged Prefrontal Cortex / metabolism Schizophrenia / genetics Up-Regulation
Dorsolateral prefrontal cortex Gene expression Grey matter Interleukin 1-beta Lateral ventricle Schizophrenia

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 03 2018
revised: 09 07 2018
accepted: 09 09 2018
pubmed: 18 9 2018
medline: 5 3 2020
entrez: 18 9 2018
Statut: ppublish

Résumé

We investigated IL1B genetic variation previously associated with risk for transition to psychosis for its association with gene expression in human post-mortem dorsolateral prefrontal cortex (DLPFC) from 74 (37 schizophrenia, 37 control) individuals and brain structure in 92 (44 schizophrenia, 48 control) living individuals. The IL1B A-G-T 'risk for psychosis transition' haplotype (rs16944|rs4848306|rs12621220) was associated with upregulation of IL1B mRNA expression in the DLPFC as well as reduced total grey matter and left middle frontal volumes and enlarged left lateral ventricular volume. Our results suggest IL1B genetic variation may confer psychosis risk via elevated mRNA expression and/or brain structure abnormalities.

Identifiants

DOI: 10.1016/j.schres.2018.09.008 PMID: 30220520
pubmed: 30220520
pii: S0920-9964(18)30558-9
doi: 10.1016/j.schres.2018.09.008
pii:
doi:

Substances chimiques

IL1B protein, human 0
Interleukin-1beta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-205

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Md Shaki Mostaid (MS)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia.

Stefanos Dimitrakopoulos (S)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia; 1st Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece.

Cassandra Wannan (C)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia.

Vanessa Cropley (V)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia.

Cynthia Shannon Weickert (CS)

Schizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Sydney, Australia; School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia; Department of Neuroscience & Physiology, Upstate Medical University, Syracuse, New York 13210, USA.

Ian P Everall (IP)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia; Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia; NorthWestern Mental Health, Melbourne, Victoria, Australia; Institute of Psychiatry, Psychology, and Neuroscience, King's College London, UK.

Christos Pantelis (C)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia; Centre for Neural Engineering, The University of Melbourne, Carlton, VIC, Australia; NorthWestern Mental Health, Melbourne, Victoria, Australia.

Chad A Bousman (CA)

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Carlton South, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, VIC, Australia; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Departments of Medical Genetics, Psychiatry, and Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada. Electronic address: chad.bousman@ucalgary.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Système nerveux › Système nerveux central › Moelle spinale › Substance grise › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Haplotypes › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Monokines › Interleukine-1 › Interleukine-1 bêta › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Ventricules cérébraux › Ventricules latéraux › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Lobe frontal › Cortex préfrontal › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Schizophrénie › An Interleukin-1 beta (IL1B) haplotype linked...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › An Interleukin-1 beta (IL1B) haplotype linked...